NO20063017L - Protein NMB0928 og anvendelse derav i farmasoytiske formuleringer - Google Patents

Protein NMB0928 og anvendelse derav i farmasoytiske formuleringer

Info

Publication number
NO20063017L
NO20063017L NO20063017A NO20063017A NO20063017L NO 20063017 L NO20063017 L NO 20063017L NO 20063017 A NO20063017 A NO 20063017A NO 20063017 A NO20063017 A NO 20063017A NO 20063017 L NO20063017 L NO 20063017L
Authority
NO
Norway
Prior art keywords
formulations
origin
ability
diseases
nmb0928
Prior art date
Application number
NO20063017A
Other languages
English (en)
Norwegian (no)
Inventor
Sonia Gonzalez Blanco
Gerardo Enrique Guillen Nieto
Rolando Pajon Feyt
Yasser Perera Negrin
Darien Garcia Diaz
Olivia Niebla Perez
Evelin Caballero Menendez
Gretel Sardinas Garcia
Lazaro Hiram Betancourt Nunez
Lila Rosa Castellanos Serra
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of NO20063017L publication Critical patent/NO20063017L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NO20063017A 2003-12-03 2006-06-28 Protein NMB0928 og anvendelse derav i farmasoytiske formuleringer NO20063017L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2002008620030286A CU23236A1 (es) 2003-12-03 2003-12-03 PROTEINA NMB0928 Y SU USO EN FORMULACIONES FARMACéUTICAS P
PCT/CU2004/000016 WO2005054282A1 (es) 2003-12-03 2004-12-02 Proteína nmb0928 y su uso en formulaciones farmaceuticas

Publications (1)

Publication Number Publication Date
NO20063017L true NO20063017L (no) 2006-09-01

Family

ID=40091627

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063017A NO20063017L (no) 2003-12-03 2006-06-28 Protein NMB0928 og anvendelse derav i farmasoytiske formuleringer

Country Status (16)

Country Link
US (1) US20070128230A1 (de)
EP (1) EP1693379B1 (de)
KR (1) KR20060124625A (de)
CN (1) CN100549027C (de)
AR (1) AR046937A1 (de)
AT (1) ATE456573T1 (de)
AU (1) AU2004294377A1 (de)
BR (1) BRPI0417334A (de)
CA (1) CA2547537A1 (de)
CU (1) CU23236A1 (de)
DE (1) DE602004025377D1 (de)
NO (1) NO20063017L (de)
NZ (1) NZ547521A (de)
RU (1) RU2335505C2 (de)
WO (1) WO2005054282A1 (de)
ZA (1) ZA200604492B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23549A1 (es) * 2005-12-29 2010-07-20 Ct Ingenieria Genetica Biotech Composiciones farmacéuticas que contienen la proteína nma0939
CU23575A1 (es) * 2006-03-31 2010-09-30 Ct Ingenieria Genetica Biotech Composición farmacéutica que comprende la proteína nmb0606
CU23572A1 (es) * 2006-03-31 2010-09-30 Ct Ingenieria Genetica Biotech Composición farmacéutica que comprende la proteína nmb0938
KR102906912B1 (ko) 2016-09-02 2026-01-05 사노피 파스퇴르 인크 네이세리아 메닌기티디스 백신

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4219821A1 (de) * 1992-06-17 1993-12-23 Boehringer Mannheim Gmbh Spezifischer Nachweis von Neisseria Gonorrhoeae
CU22559A1 (es) * 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
EP2261352A3 (de) * 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Antigene und Zusammensetzungen gegen Neisseria meningitidis
GB9911683D0 (en) * 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9911692D0 (en) * 1999-05-19 1999-07-21 Chiron Spa Antigenic combinations
RU2281956C2 (ru) * 1999-10-29 2006-08-20 Чирон С.Р.Л. Антигенные пептиды neisseria
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens

Also Published As

Publication number Publication date
AU2004294377A1 (en) 2005-06-16
ATE456573T1 (de) 2010-02-15
EP1693379B1 (de) 2010-01-27
BRPI0417334A (pt) 2007-03-27
CN100549027C (zh) 2009-10-14
CU23236A1 (es) 2007-09-26
CN1890261A (zh) 2007-01-03
WO2005054282A1 (es) 2005-06-16
CA2547537A1 (en) 2005-06-16
RU2335505C2 (ru) 2008-10-10
AR046937A1 (es) 2006-01-04
EP1693379A1 (de) 2006-08-23
US20070128230A1 (en) 2007-06-07
KR20060124625A (ko) 2006-12-05
DE602004025377D1 (de) 2010-03-18
RU2006123414A (ru) 2008-01-10
NZ547521A (en) 2009-07-31
ZA200604492B (en) 2007-05-30

Similar Documents

Publication Publication Date Title
KR101145190B1 (ko) 사람 파필로마바이러스 폴리펩타이드 및 면역원성 조성물
WO2007149715A3 (en) Novel dna sequences, vectors and proteins of avian influenza hemagglutinin
WO2007054279A3 (en) Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions
WO2007022425A3 (en) Influenza recombinant subunit vaccine
WO2008033375A3 (en) Long lasting drug formulations
UA99659C2 (uk) Мультивалентна вакцина з нативних везикул зовнішньої мембрани менінгококів, способи її застосування
NO20111324A1 (no) Rekombinant MVA-virus
NO20072854L (no) Acylerte nonadepsipeptider anvendt som lysobaktinderivater
TNSN07087A1 (en) Stable liquid formulations of plasmid dna
DK2010563T3 (da) Syntetisk MeCP2 sekvens til proteinsubstitutionsterapi
BR0309570A (pt) Fatores camp quiméricos para vacinação contra infecção por streptococcus
DE60142519D1 (de) Dna-expressionsvektoren
GB2458057A (en) Francisella strain for live vaccine
NO20062948L (no) Promotere for ekspresjon i modifisert vaccinia-virus Ankara
NO20063017L (no) Protein NMB0928 og anvendelse derav i farmasoytiske formuleringer
NO20055209L (no) Peptabody for cancerbehandling
NO20060813L (no) Syntetisk gen som koder for human epidermalvekstfaktor 2/NEU og andvendelser derav
NO20044947L (no) MUC-1 antigen med redusert antall VNTR gjentagene enheter
Wang et al. Two oral HBx vaccines delivered by live attenuated Salmonella: both eliciting effective anti-tumor immunity
NO20063020L (no) Protein NMB1125 og anvendelse derav i farmasoytiske formuleringer
CY1107560T1 (el) Ζωντανα εξασθενημενα βακτηρια για χρηση σε εμβολιο
NO20084524L (no) Farmasoytisk sammensetning inneholdende NMB0938-protein
DE602004024968D1 (de) Francisella-stamm für lebenden impfstoff
NO20084525L (no) Farmasoytiske sammensetninger inneholdende NMB0606-protein
WO2025024776A3 (en) Compositions comprising xbp1 fragments and methods of use in gene therapy

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application